# NCT04557150 (NCT04557150)

> A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04557150
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Multiple Myeloma
- Interventions: Forimtamig
- Enrollment: 225
- Primary outcome: Percentage of Participants with Adverse Events (AEs)
- Primary outcome: Percentage of Participants with Dose Limiting Toxicities (DLTs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04557150